Back to Journals » Vascular Health and Risk Management » Volume 6
Effect of lipopenic and hypotensive treatment on homocysteine levels in type 2 diabetics
Authors Oudi ME, Aouni Z, Ouertani H, Mazigh C, Machghoul S
Published 13 May 2010 Volume 2010:6 Pages 327—332
Review by Single anonymous peer review
Peer reviewer comments 2
Mabrouka El Oudi1, Zied Aouni1, Haroun Ouertani2, Chakib Mazigh2, Salem Machghoul1
1Département de biochimie, 2Service d’endocrinologie, Hôpital militaire de Tunis, 1008 Montfleury, Tunisie
Aim: Evaluate the effect of lipopenic and hypotensive treatment on homocysteine levels.
Methods: We recruited 145 type 2 diabetics and 130 control subjects. Thirty-seven diabetics had no complications, 54 had microvascular complications and 54 had macrovascular complications. We determined the parameters homocysteine of lipid, vitamin B12, triglycerides, and folates for all subjects. Associated treatments used one or more of the following drugs, statin, fibrate, angiotensin-converting enzyme inhibitor and beta-blockers.
Results: Hyperhomocysteinemia was present in 35.6% of patients. Diabetics had elevated serum levels of triglycerides (P < 0.001), homocysteine (P < 0.01), folates (P < 0.01) and vitamin B12 (P < 0.001). A strong association was found between type 2 diabetes and hyperhomocysteinemia (P < 0.001). Diabetics with associated treatment had elevated homocysteine, vitamin B12 and folate levels when compared to diabetes-free controls. For diabetics with macrovascular complications, we found significant differences in homocysteine (P = 0.010) and folate (P = 0.014) between those taking associated drugs and those who did not. For diabetics with microvascular complications, a significant difference was found in folate only (P = 0.012).
Conclusion: Drugs used for hypertension and hyperlipidemia may have an effect on homocysteine levels, for this reason the interaction between drug action and homocysteine levels should be taken into consideration.
Keywords: type 2 diabetes, complications, homocysteine, hypolipemiant drug, hypotensive drug
© 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.